Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy.
- DOI
- 10.1186/s13148-026-02205-x
- Published
- 2026 Jul 21
- Container
- Clinical epigenetics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13148-026-02205-x,
title = {Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy.},
author = {Pamart D and Cuvelier B and Govaerts A and Chapelier M and Herzog M and Retter A and Bygott T and Turatsinze JV and Berman BP and Micallef J},
year = {2026},
journal = {Clinical epigenetics},
doi = {10.1186/s13148-026-02205-x},
url = {https://doi.org/10.1186/s13148-026-02205-x}
}RIS
TY - JOUR TI - Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy. AU - Pamart D AU - Cuvelier B AU - Govaerts A AU - Chapelier M AU - Herzog M AU - Retter A AU - Bygott T AU - Turatsinze JV AU - Berman BP AU - Micallef J PY - 2026 JO - Clinical epigenetics DO - 10.1186/s13148-026-02205-x UR - https://doi.org/10.1186/s13148-026-02205-x ER -
APA
D, P., B, C., A, G., M, C., M, H., A, R., T, B., JV, T., BP, B., & J, M. (2026). Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy.. Clinical epigenetics. https://doi.org/10.1186/s13148-026-02205-x
Source records
- pubmed · retrieved 2026-09-25T23:14:31.698Z